advertisement
11.3.3 Apraclonidine, brimonidine (8)
Showing records 1 to 8
Display all abstracts in classification 11.3.3 Apraclonidine, brimonidine
Search within classification 11.3.3 Apraclonidine, brimonidine5674 The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension (corrected and republished article originally printed in Am J Ophthalmol 1999 128(6):697-701)
Carlsson AM; Chauhan BC; Lee AA; Leblanc RP
American Journal of Ophthalmology 2000; 129: 297-301
5785 Alpha-2 adrenergic agonists in the treatment of glaucoma
Apatachioae I; Chiselita D
Oftalmologia 1999; 47:35-40
5786 Clinical investigation: Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma
Centofanti M; Manni G; Gregori D; Cocco F; Lorenzano D; Bucci MG
Graefe's Archive for Clinical and Experimental Ophthalmology 2000; 238: 302-305
5787 A comparison of the effectiveness of dorzolamide and acetazolamide in preventing-postoperative intraocular pressure rise following phacoemulsification
Chakraborty P; Villada JR; Tinu AT
Journal of the Royal College of Surgeons of Edinburgh 1999; 44/6:411-412
5788 Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine
Geyer O; Schmidt KG; Pianka P; Neudorfer M; Lazar M
Graefe's Archive for Clinical and Experimental Ophthalmology 2000; 238: 149-152
5789 Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension
Lee DA
Clinical Therapeutics 2000; 22:53-65
5790 The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial: Glaucoma Trial Study Group
Lee DA; Gornbein J; Abrams C
Journal of Ocular Pharmacology and Therapeutics 2000; 16:3-18
5791 Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results: Brimonidine Study Group II
Melamed S; David R
Clinical Therapeutics 2000; 22:103-111